Glioblastoma (GBM) is the most prevalent malignant brain tumor in adults, causing over 1 % of cancer-related deaths. Although there are many histological subtypes as classified by the World Health Organization, gliomas are typically characterized by their angiogenic and infiltrative nature. It has been demonstrated that GBM can switch from an angiogenic to invasive phenotype and vice versa. Treatment for high-grade tumors such as glioblastoma multiforme (GBM) and anaplastic astrocytoma usually includes surgery to debulk the tumor and postoperative adjuvant therapies. Recently, antiangiogenic therapies have also been investigated in clinical trials. Besides treatment-induced symptoms, these therapies may impact the biology of GBM by favoring an infiltrative phenotype, which may cause evasive resistance. Thus, the risk/benefit of these therapies has to be critically evaluated and patient populations that may benefit from these treatments identified.